I-Mab (IMAB) - Net Assets
Based on the latest financial reports, I-Mab (IMAB) has net assets worth $258.92 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($277.41 Million) and total liabilities ($18.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check I-Mab (IMAB) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $258.92 Million |
| % of Total Assets | 93.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | -96.43% |
| 10-Year Change | N/A |
| Growth Volatility | 25.93 |
I-Mab - Net Assets Trend (2017–2024)
This chart illustrates how I-Mab's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is I-Mab worth.
Annual Net Assets for I-Mab (2017–2024)
The table below shows the annual net assets of I-Mab from 2017 to 2024. Also explore net asset momentum of I-Mab to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $201.16 Million | -88.29% |
| 2023-12-31 | $1.72 Billion | -42.89% |
| 2022-12-31 | $3.01 Billion | -34.43% |
| 2021-12-31 | $4.59 Billion | -18.47% |
| 2020-12-31 | $5.63 Billion | +376.56% |
| 2019-12-31 | $-2.03 Billion | -113.03% |
| 2018-12-31 | $-955.10 Million | -218.59% |
| 2017-12-31 | $-299.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to I-Mab's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 92817900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.01% |
| Other Comprehensive Income | $33.38 Million | 16.60% |
| Other Components | $1.45 Billion | 722.71% |
| Total Equity | $201.16 Million | 100.00% |
I-Mab Competitors by Market Cap
The table below lists competitors of I-Mab ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zenitron Corp
TW:3028
|
$456.69 Million |
|
Zhejiang Jianye Chemical Co Ltd
SHG:603948
|
$456.76 Million |
|
Shenzhen Xfh Technology Co Ltd
SHE:300890
|
$456.79 Million |
|
Issta Lines Ltd
TA:ISTA
|
$456.99 Million |
|
Hangzhou Heshun Technology Co.LTD.
SHE:301237
|
$456.44 Million |
|
DONGGUAN R.COMMERC. H YC1
F:857
|
$456.36 Million |
|
Beijing Leadman Biochemistry Co Ltd
SHE:300289
|
$456.14 Million |
|
Delek Automotive Systems Ltd
TA:DLEA
|
$456.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in I-Mab's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,718,156,000 to 201,160,000, a change of -1,516,996,000 (-88.3%).
- Net loss of 162,257,000 reduced equity.
- Share repurchases of 335,000 reduced equity.
- Other comprehensive income decreased equity by 6,387,000.
- Other factors decreased equity by 1,348,017,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-162.26 Million | -80.66% |
| Share Repurchases | $335.00K | -0.17% |
| Other Comprehensive Income | $-6.39 Million | -3.18% |
| Other Changes | $-1.35 Billion | -670.12% |
| Total Change | $- | -88.29% |
Book Value vs Market Value Analysis
This analysis compares I-Mab's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-5.15 | $3.96 | x |
| 2018-12-31 | $-16.42 | $3.96 | x |
| 2019-12-31 | $-34.98 | $3.96 | x |
| 2020-12-31 | $82.31 | $3.96 | x |
| 2021-12-31 | $60.40 | $3.96 | x |
| 2022-12-31 | $36.46 | $3.96 | x |
| 2023-12-31 | $20.64 | $3.96 | x |
| 2024-12-31 | $2.48 | $3.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently I-Mab utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-80.66%) is below the historical average (-36.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -2580.82% | 0.01x | 0.00x | $-268.26 Million |
| 2018 | 0.00% | -749.02% | 0.02x | 0.00x | $-307.32 Million |
| 2019 | 0.00% | -4950.00% | 0.02x | 0.00x | $-1.28 Billion |
| 2020 | 8.37% | 30.53% | 0.24x | 1.13x | $-91.80 Million |
| 2021 | -50.82% | -2648.70% | 0.02x | 1.23x | $-2.79 Billion |
| 2022 | -83.35% | 0.00% | 0.00x | 1.35x | $-2.81 Billion |
| 2023 | -85.31% | -32674.02% | 0.00x | 1.52x | $-1.64 Billion |
| 2024 | -80.66% | 0.00% | 0.00x | 1.06x | $-182.37 Million |
Industry Comparison
This section compares I-Mab's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| I-Mab (IMAB) | $258.92 Million | 0.00% | 0.07x | $456.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more